| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 93 | 2026 | 2644 | 8.330 |
Why?
|
| Trastuzumab | 36 | 2026 | 148 | 3.860 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 39 | 2026 | 1350 | 3.690 |
Why?
|
| Antineoplastic Agents | 24 | 2023 | 1804 | 2.300 |
Why?
|
| Quinazolines | 20 | 2026 | 181 | 2.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 24 | 2025 | 569 | 2.110 |
Why?
|
| Neoadjuvant Therapy | 29 | 2026 | 397 | 1.960 |
Why?
|
| Triple Negative Breast Neoplasms | 14 | 2026 | 287 | 1.950 |
Why?
|
| Receptors, Estrogen | 31 | 2024 | 727 | 1.900 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2025 | 821 | 1.620 |
Why?
|
| Aromatase Inhibitors | 7 | 2023 | 78 | 1.570 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2019 | 256 | 1.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 6 | 2025 | 81 | 0.980 |
Why?
|
| Biomarkers, Tumor | 14 | 2026 | 1616 | 0.820 |
Why?
|
| Female | 92 | 2026 | 70858 | 0.780 |
Why?
|
| Estrogen Antagonists | 2 | 2022 | 93 | 0.750 |
Why?
|
| Neoplasm Staging | 14 | 2026 | 1315 | 0.720 |
Why?
|
| Arthralgia | 2 | 2019 | 75 | 0.710 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2017 | 253 | 0.650 |
Why?
|
| Humans | 105 | 2026 | 131151 | 0.620 |
Why?
|
| Cholecalciferol | 1 | 2019 | 20 | 0.610 |
Why?
|
| Middle Aged | 44 | 2026 | 28781 | 0.590 |
Why?
|
| Brain Neoplasms | 5 | 2024 | 1283 | 0.560 |
Why?
|
| Aged | 33 | 2026 | 21172 | 0.550 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2026 | 139 | 0.530 |
Why?
|
| Chemotherapy, Adjuvant | 12 | 2024 | 389 | 0.520 |
Why?
|
| Paclitaxel | 5 | 2026 | 134 | 0.510 |
Why?
|
| Alopecia | 1 | 2017 | 42 | 0.510 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2025 | 129 | 0.510 |
Why?
|
| Scalp | 1 | 2017 | 58 | 0.500 |
Why?
|
| ErbB Receptors | 6 | 2014 | 294 | 0.490 |
Why?
|
| Quinolines | 4 | 2024 | 118 | 0.490 |
Why?
|
| Molecular Targeted Therapy | 9 | 2025 | 383 | 0.480 |
Why?
|
| Hypothermia, Induced | 1 | 2017 | 164 | 0.470 |
Why?
|
| Taxoids | 6 | 2025 | 71 | 0.460 |
Why?
|
| Adult | 33 | 2026 | 31607 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2024 | 1250 | 0.460 |
Why?
|
| Carcinoma | 2 | 2015 | 283 | 0.450 |
Why?
|
| Treatment Outcome | 21 | 2025 | 12885 | 0.440 |
Why?
|
| Circulating Tumor DNA | 2 | 2026 | 41 | 0.430 |
Why?
|
| Immunoconjugates | 2 | 2025 | 50 | 0.420 |
Why?
|
| Signal Transduction | 19 | 2025 | 4655 | 0.420 |
Why?
|
| Sirolimus | 2 | 2014 | 231 | 0.420 |
Why?
|
| Endoribonucleases | 2 | 2024 | 84 | 0.410 |
Why?
|
| Aged, 80 and over | 13 | 2025 | 6879 | 0.400 |
Why?
|
| Disease-Free Survival | 8 | 2026 | 910 | 0.390 |
Why?
|
| Cell Line, Tumor | 19 | 2024 | 3670 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 5 | 2023 | 1007 | 0.380 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2019 | 78 | 0.350 |
Why?
|
| Mastectomy | 5 | 2021 | 75 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2025 | 610 | 0.340 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 227 | 0.330 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2018 | 1001 | 0.310 |
Why?
|
| Proteogenomics | 2 | 2022 | 108 | 0.310 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2025 | 79 | 0.310 |
Why?
|
| Maytansine | 2 | 2021 | 4 | 0.290 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2025 | 126 | 0.280 |
Why?
|
| Pyridines | 4 | 2026 | 258 | 0.280 |
Why?
|
| Nitriles | 4 | 2024 | 165 | 0.270 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 671 | 0.270 |
Why?
|
| Triazoles | 4 | 2024 | 144 | 0.270 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2019 | 345 | 0.260 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2018 | 92 | 0.250 |
Why?
|
| Bridged-Ring Compounds | 3 | 2025 | 19 | 0.250 |
Why?
|
| Endpoint Determination | 1 | 2026 | 55 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 1270 | 0.240 |
Why?
|
| Mice, Nude | 9 | 2018 | 715 | 0.240 |
Why?
|
| Receptors, Progesterone | 8 | 2018 | 683 | 0.240 |
Why?
|
| Indoles | 2 | 2018 | 201 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2017 | 1988 | 0.220 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2025 | 59 | 0.220 |
Why?
|
| Piperazines | 3 | 2021 | 269 | 0.220 |
Why?
|
| RNA, Double-Stranded | 1 | 2024 | 58 | 0.220 |
Why?
|
| Pyroptosis | 1 | 2024 | 34 | 0.210 |
Why?
|
| Capecitabine | 3 | 2026 | 19 | 0.210 |
Why?
|
| Prognosis | 11 | 2026 | 4937 | 0.210 |
Why?
|
| Anthracyclines | 2 | 2017 | 43 | 0.210 |
Why?
|
| Research Design | 2 | 2022 | 722 | 0.210 |
Why?
|
| Lymphatic Metastasis | 4 | 2013 | 431 | 0.210 |
Why?
|
| Meningeal Neoplasms | 1 | 2026 | 203 | 0.200 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2023 | 21 | 0.200 |
Why?
|
| Proteomics | 2 | 2025 | 600 | 0.200 |
Why?
|
| Catechin | 2 | 2014 | 15 | 0.200 |
Why?
|
| Mastectomy, Segmental | 2 | 2021 | 39 | 0.200 |
Why?
|
| Neoplasm Metastasis | 4 | 2025 | 704 | 0.200 |
Why?
|
| Proteostasis | 1 | 2023 | 35 | 0.200 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2023 | 137 | 0.190 |
Why?
|
| Tamoxifen | 6 | 2018 | 349 | 0.190 |
Why?
|
| Clinical Decision-Making | 1 | 2025 | 310 | 0.190 |
Why?
|
| Gene Expression | 5 | 2020 | 1503 | 0.190 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 173 | 0.190 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2022 | 30 | 0.190 |
Why?
|
| Epidermal Growth Factor | 2 | 2021 | 116 | 0.190 |
Why?
|
| Mutation | 8 | 2025 | 6155 | 0.190 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2022 | 52 | 0.180 |
Why?
|
| Animals | 20 | 2024 | 34349 | 0.180 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2022 | 136 | 0.180 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2021 | 25 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 1 | 2023 | 143 | 0.180 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2023 | 176 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2022 | 237 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 49 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 64 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 565 | 0.170 |
Why?
|
| Survival Analysis | 5 | 2020 | 1524 | 0.160 |
Why?
|
| Mevalonic Acid | 1 | 2019 | 20 | 0.150 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 741 | 0.150 |
Why?
|
| Pneumonia | 1 | 2023 | 345 | 0.150 |
Why?
|
| Genes, erbB-2 | 2 | 2010 | 32 | 0.150 |
Why?
|
| Cinnamates | 1 | 2018 | 16 | 0.150 |
Why?
|
| Estrogen Receptor alpha | 2 | 2025 | 434 | 0.140 |
Why?
|
| Androstadienes | 2 | 2017 | 50 | 0.140 |
Why?
|
| Up-Regulation | 4 | 2014 | 830 | 0.140 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 1 | 2018 | 18 | 0.140 |
Why?
|
| Mice | 15 | 2024 | 18449 | 0.140 |
Why?
|
| Risk Factors | 4 | 2021 | 10923 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2019 | 360 | 0.140 |
Why?
|
| Receptors, Calcitriol | 1 | 2017 | 59 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2024 | 805 | 0.130 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2017 | 16 | 0.130 |
Why?
|
| Radiopharmaceuticals | 3 | 2025 | 165 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 159 | 0.130 |
Why?
|
| Fluorouracil | 2 | 2014 | 134 | 0.130 |
Why?
|
| Quality of Life | 3 | 2017 | 2100 | 0.130 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 43 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2019 | 372 | 0.120 |
Why?
|
| Diphosphonates | 1 | 2016 | 41 | 0.120 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1529 | 0.120 |
Why?
|
| Dasatinib | 1 | 2016 | 53 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 431 | 0.120 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1250 | 0.120 |
Why?
|
| Bone Density Conservation Agents | 1 | 2016 | 58 | 0.120 |
Why?
|
| Gene Expression Profiling | 4 | 2016 | 1828 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2019 | 333 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2019 | 448 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2016 | 207 | 0.120 |
Why?
|
| Primary Prevention | 1 | 2017 | 174 | 0.120 |
Why?
|
| Neoplasm Transplantation | 2 | 2019 | 363 | 0.110 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 369 | 0.110 |
Why?
|
| Carboplatin | 3 | 2022 | 79 | 0.110 |
Why?
|
| Imidazoles | 1 | 2016 | 220 | 0.110 |
Why?
|
| Deoxycytidine | 1 | 2014 | 82 | 0.110 |
Why?
|
| Transcriptome | 3 | 2016 | 1151 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2025 | 2290 | 0.110 |
Why?
|
| Camptothecin | 2 | 2025 | 78 | 0.110 |
Why?
|
| Tea | 1 | 2014 | 18 | 0.110 |
Why?
|
| Breast | 3 | 2022 | 215 | 0.110 |
Why?
|
| Neoplasm, Residual | 2 | 2026 | 137 | 0.110 |
Why?
|
| Apoptosis | 4 | 2019 | 1861 | 0.100 |
Why?
|
| Time Factors | 6 | 2021 | 6282 | 0.100 |
Why?
|
| Acneiform Eruptions | 1 | 2013 | 4 | 0.100 |
Why?
|
| Pyrroles | 1 | 2014 | 186 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2010 | 92 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2026 | 6453 | 0.100 |
Why?
|
| Drug Eruptions | 1 | 2013 | 34 | 0.100 |
Why?
|
| Tumor Microenvironment | 3 | 2025 | 697 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2024 | 1443 | 0.100 |
Why?
|
| Estrogens | 3 | 2018 | 437 | 0.100 |
Why?
|
| Mammaplasty | 1 | 2013 | 44 | 0.100 |
Why?
|
| Cell Proliferation | 6 | 2018 | 2464 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2014 | 138 | 0.090 |
Why?
|
| Estradiol | 4 | 2018 | 483 | 0.090 |
Why?
|
| Mucin-4 | 1 | 2012 | 12 | 0.090 |
Why?
|
| Young Adult | 3 | 2025 | 10049 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 293 | 0.090 |
Why?
|
| Jejunal Neoplasms | 1 | 2012 | 5 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2016 | 861 | 0.090 |
Why?
|
| Jejunal Diseases | 1 | 2012 | 11 | 0.090 |
Why?
|
| Phyllodes Tumor | 1 | 2012 | 9 | 0.090 |
Why?
|
| Age Factors | 3 | 2021 | 2869 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2021 | 3680 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2026 | 643 | 0.090 |
Why?
|
| Everolimus | 1 | 2012 | 48 | 0.090 |
Why?
|
| Biomarkers | 3 | 2020 | 3379 | 0.090 |
Why?
|
| Cisplatin | 2 | 2026 | 284 | 0.090 |
Why?
|
| Integrin beta1 | 1 | 2011 | 54 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 441 | 0.090 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2020 | 84 | 0.090 |
Why?
|
| MCF-7 Cells | 3 | 2018 | 210 | 0.090 |
Why?
|
| Intussusception | 1 | 2012 | 54 | 0.090 |
Why?
|
| Phosphorylation | 4 | 2019 | 1567 | 0.090 |
Why?
|
| Intention to Treat Analysis | 2 | 2025 | 61 | 0.080 |
Why?
|
| Triazines | 1 | 2010 | 33 | 0.080 |
Why?
|
| Postmenopause | 2 | 2024 | 149 | 0.080 |
Why?
|
| Women's Health | 1 | 2012 | 143 | 0.080 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 330 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 1071 | 0.080 |
Why?
|
| Guilt | 1 | 2010 | 16 | 0.080 |
Why?
|
| Frozen Sections | 1 | 2010 | 28 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2017 | 1094 | 0.080 |
Why?
|
| Spirituality | 1 | 2010 | 48 | 0.080 |
Why?
|
| Mice, SCID | 3 | 2019 | 579 | 0.080 |
Why?
|
| Ki-67 Antigen | 2 | 2024 | 104 | 0.070 |
Why?
|
| Self Concept | 1 | 2010 | 162 | 0.070 |
Why?
|
| Remission Induction | 2 | 2020 | 307 | 0.070 |
Why?
|
| Neoplasms | 1 | 2023 | 2962 | 0.070 |
Why?
|
| ROC Curve | 2 | 2026 | 614 | 0.070 |
Why?
|
| Positron-Emission Tomography | 2 | 2023 | 294 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2010 | 356 | 0.070 |
Why?
|
| Survivors | 1 | 2010 | 351 | 0.070 |
Why?
|
| DNA Repair | 1 | 2010 | 563 | 0.060 |
Why?
|
| RNA, Small Interfering | 3 | 2016 | 666 | 0.060 |
Why?
|
| Phenotype | 3 | 2013 | 4497 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2025 | 1632 | 0.060 |
Why?
|
| Tissue Distribution | 2 | 2019 | 365 | 0.060 |
Why?
|
| Heterografts | 2 | 2018 | 194 | 0.060 |
Why?
|
| Oxazoles | 1 | 2026 | 21 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2018 | 154 | 0.060 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2025 | 38 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2020 | 428 | 0.060 |
Why?
|
| United States | 4 | 2025 | 11743 | 0.050 |
Why?
|
| Calibration | 1 | 2024 | 96 | 0.050 |
Why?
|
| Cell Survival | 2 | 2018 | 852 | 0.050 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2024 | 123 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 5264 | 0.050 |
Why?
|
| src-Family Kinases | 2 | 2016 | 92 | 0.050 |
Why?
|
| Frailty | 1 | 2026 | 139 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2026 | 228 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 131 | 0.050 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2024 | 129 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2017 | 485 | 0.050 |
Why?
|
| Disease Progression | 3 | 2014 | 2201 | 0.050 |
Why?
|
| Purines | 1 | 2023 | 115 | 0.050 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 19 | 0.050 |
Why?
|
| Inflammasomes | 1 | 2024 | 156 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2014 | 189 | 0.050 |
Why?
|
| Amenorrhea | 1 | 2021 | 19 | 0.040 |
Why?
|
| Survival Rate | 2 | 2019 | 2145 | 0.040 |
Why?
|
| Mice, Inbred NOD | 2 | 2013 | 301 | 0.040 |
Why?
|
| Depression | 1 | 2010 | 1331 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 324 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2021 | 120 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 1403 | 0.040 |
Why?
|
| Homologous Recombination | 1 | 2020 | 99 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2023 | 610 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 34 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 76 | 0.040 |
Why?
|
| Decision Making | 1 | 2025 | 681 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 989 | 0.040 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 6 | 0.040 |
Why?
|
| Keratins | 1 | 2019 | 51 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2019 | 84 | 0.040 |
Why?
|
| Craniotomy | 1 | 2019 | 100 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 17513 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 172 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2019 | 228 | 0.040 |
Why?
|
| Cell Separation | 1 | 2019 | 221 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 1009 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2023 | 1022 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 1237 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2020 | 661 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2019 | 5101 | 0.030 |
Why?
|
| Oncogene Addiction | 1 | 2017 | 3 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 755 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 749 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 152 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 704 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2007 | 261 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2022 | 1083 | 0.030 |
Why?
|
| Vitamin D | 1 | 2017 | 189 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 173 | 0.030 |
Why?
|
| Cell Count | 1 | 2014 | 220 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 92 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2014 | 33 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 4686 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 139 | 0.030 |
Why?
|
| South America | 1 | 2014 | 45 | 0.030 |
Why?
|
| Doxycycline | 1 | 2014 | 115 | 0.030 |
Why?
|
| South Africa | 1 | 2014 | 104 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 227 | 0.030 |
Why?
|
| Australia | 1 | 2014 | 173 | 0.030 |
Why?
|
| North America | 1 | 2014 | 256 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 382 | 0.020 |
Why?
|
| Random Allocation | 1 | 2014 | 421 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 1741 | 0.020 |
Why?
|
| Hospitals, Public | 1 | 2013 | 49 | 0.020 |
Why?
|
| Ploidies | 1 | 2012 | 35 | 0.020 |
Why?
|
| Europe | 1 | 2014 | 371 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2963 | 0.020 |
Why?
|
| Cetuximab | 1 | 2012 | 13 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 793 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 694 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 175 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2012 | 87 | 0.020 |
Why?
|
| Receptor, ErbB-3 | 1 | 2011 | 17 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2013 | 117 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 340 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2011 | 23 | 0.020 |
Why?
|
| Breast Neoplasms, Male | 1 | 2011 | 17 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2011 | 33 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 238 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 774 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 430 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 146 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2011 | 110 | 0.020 |
Why?
|
| Triglycerides | 1 | 2014 | 607 | 0.020 |
Why?
|
| Cholesterol | 1 | 2014 | 543 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3835 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 96 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 2010 | 66 | 0.020 |
Why?
|
| Epirubicin | 1 | 2010 | 7 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 292 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 3435 | 0.020 |
Why?
|
| Antibodies | 1 | 2011 | 357 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 726 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 318 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 419 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 586 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2010 | 179 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1396 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 600 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 324 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 961 | 0.020 |
Why?
|
| Genomics | 1 | 2017 | 1618 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1626 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2849 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2010 | 439 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1590 | 0.020 |
Why?
|
| Smoking | 1 | 2013 | 925 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 598 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2008 | 238 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 3169 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 434 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 1680 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 3398 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2005 | 35 | 0.010 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2005 | 39 | 0.010 |
Why?
|
| Cell Division | 1 | 2007 | 724 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 1134 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2013 | 3860 | 0.010 |
Why?
|
| Male | 2 | 2024 | 64940 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1397 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1615 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 3130 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 4016 | 0.010 |
Why?
|